Therapeutic effects of adipose mesenchymal stem cell-derived exosomes on limbal stem cells deficiency in cats.
Ergin I., Sainkaplan S., Isik M., Cinar OO., Bayraktaroglu AG., Derkus B.
Randomized Controlled Trial with a reported sample of 15, published in Vet Res Commun (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Randomized Controlled Trial
- Journal
- Vet Res Commun (2025)
- Country
- Switzerland
- Reported sample size
- 15
- Source database
- PubMed
- PMID
- 41055800
- DOI
- 10.1007/s11259-025-10908-4
Abstract (original English)
Corneal transparency is maintained by the limbus and its stem cells, and damage or deficiency in this region leads to conjunctivalization and subsequent vision impairment. This study aims to evaluate the therapeutic effects of feline adipose mesenchymal stem cell-derived exosomes (fAD-MSCExo) in the treatment of limbal stem cell deficiency in cats. For this purpose, 30 animals presenting with severe conjunctivalization were included in the study. Cats were randomly assigned to two groups: Group 1 (n = 15), serving as the control group and receiving steroid treatment, Group 2 (n = 15), receiving fAD-MSCExo therapy. Exosomes were produced from fAD-MSCs isolated from intra-abdominal adipose tissue obtained from three healthy donor cats. Detailed ophthalmologic examination and impression cytology were performed on all animals preoperatively and on postoperative days 0, 10, and 30. Periodic acid-schiff staining was used to detect goblet cells, while Immunofluorescence staining was performed to identify K13 cytokeratin antibodies. At postoperative day 10, no significant clinical or histological differences were observed between the two groups. However, after treatment discontinuation, by postoperative day 30, clinical improvement had regressed in the steroid-treated group, whereas corneal epithelial regeneration and, consequently, limbal repair had progressed satisfactorily in the ex
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.